Zheng-Rong Lu

List of Publications by Year
in descending order

158 papers	6,399 citations	50276 46 h-index	82547 72 g-index
163 all docs	163 docs citations	163 times ranked	7322 citing authors

#	Article	IF	Citations
1	Gadoliniumâ€based contrast agents for magnetic resonance cancer imaging. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2013, 5, 1-18.	6.1	290
2	MRI detection of breast cancer micrometastases with a fibronectin-targeting contrast agent. Nature Communications, 2015, 6, 7984.	12.8	215
3	Targeted intracellular codelivery of chemotherapeutics and nucleic acid with a well-defined dendrimer-based nanoglobular carrier. Biomaterials, 2009, 30, 5660-5666.	11.4	179
4	Molecular imaging of the tumor microenvironment. Advanced Drug Delivery Reviews, 2017, 113, 24-48.	13.7	175
5	Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates. Pharmaceutical Research, 2002, 19, 396-402.	3.5	156
6	Multifunctional Cationic Lipid-Based Nanoparticles Facilitate Endosomal Escape and Reduction-Triggered Cytosolic siRNA Release. Molecular Pharmaceutics, 2014, 11, 2734-2744.	4.6	145
7	Silencing Î²3 Integrin by Targeted ECO/siRNA Nanoparticles Inhibits EMT and Metastasis of Triple-Negative Breast Cancer. Cancer Research, 2015, 75, 2316-2325.	0.9	135
8	Systemic Delivery of Tumor-Targeting siRNA Nanoparticles against an Oncogenic LncRNA Facilitates Effective Triple-Negative Breast Cancer Therapy. Bioconjugate Chemistry, 2019, 30, 907-919.	3.6	121
9	Synthesis, Characterization, and Gene Delivery of Poly-<scp>l</scp>-lysine Octa(3-aminopropyl)silsesquioxane Dendrimers: Nanoglobular Drug Carriers with Precisely Defined Molecular Architectures. Molecular Pharmaceutics, 2007, 4, 759-768.	4.6	120
10	Polymerizable Fabâ€² antibody fragments for targeting of anticancer drugs. Nature Biotechnology, 1999, 17, 1101-1104.	17.5	116
11	Alkyl Derivatives of Europium(+2) and Ytterbium(+2). Crystal Structures of Eu[C(SiMe3)3]2, Yb[C(SiMe3)2(SiMe2CHCH2)]IÂ·OEt2and Yb[C(SiMe3)2(SiMe2OMe)]IÂ·OEt2. Organometallics, 1996, 15, 4783-4790.	2.3	114
12	Targeted Systemic Delivery of a Therapeutic siRNA with a Multifunctional Carrier Controls Tumor Proliferation in Mice. Molecular Pharmaceutics, 2009, 6, 738-746.	4.6	111
13	Antigen Responsive Hydrogels Based on Polymerizable Antibody Fabâ€² Fragment. Macromolecular Bioscience, 2003, 3, 296-300.	4.1	109
14	Design of novel bioconjugates for targeted drug delivery. Journal of Controlled Release, 2002, 78, 165-173.	9.9	99
15	Poly(l-glutamic acid) Gd(III)-DOTA Conjugate with a Degradable Spacer for Magnetic Resonance Imaging. Bioconjugate Chemistry, 2003, 14, 715-719.	3.6	95
16	Novel Polymerizable Surfactants with pH-Sensitive Amphiphilicity and Cell Membrane Disruption for Efficient siRNA Delivery. Bioconjugate Chemistry, 2007, 18, 2169-2177.	3.6	95
17	Design and evaluation of new pH-sensitive amphiphilic cationic lipids for siRNA delivery. Journal of Controlled Release, 2013, 171, 296-307.	9.9	87
18	A Peptide Targeted Contrast Agent Specific to Fibrin-Fibronectin Complexes for Cancer Molecular Imaging with MRI. Bioconjugate Chemistry, 2008, 19, 2300-2303.	3.6	85

#	Article	IF	Citations
19	Drug Delivery in Cancer Therapy, Quo Vadis?. Molecular Pharmaceutics, 2018, 15, 3603-3616.	4.6	85
20	EDB Fibronectin Specific Peptide for Prostate Cancer Targeting. Bioconjugate Chemistry, 2015, 26, 830-838.	3.6	82
21	Targeting fibronectin for cancer imaging and therapy. Journal of Materials Chemistry B, 2017, 5, 639-654.	5.8	82
22	Peptide-Targeted Nanoglobular Gd-DOTA Monoamide Conjugates for Magnetic Resonance Cancer Molecular Imaging. Biomacromolecules, 2010, 11, 754-761.	5.4	80
23	Biorecognizable HPMA copolymerâ€“drug conjugates for colon-specific delivery of 9-aminocamptothecin. Journal of Controlled Release, 2001, 75, 365-379.	9.9	76
24	A peptide-targeted delivery system with pH-sensitive amphiphilic cell membrane disruption for efficient receptor-mediated siRNA delivery. Journal of Controlled Release, 2009, 134, 207-213.	9.9	73
25	PEG-g-poly(GdDTPA-co-l-cystine):â€‰ A Biodegradable Macromolecular Blood Pool Contrast Agent for MR Imaging. Bioconjugate Chemistry, 2004, 15, 1424-1430.	3.6	69
26	In Vivo Evaluation of a PAMAM-Cystamine-(Gd-DO3A) Conjugate as a Biodegradable Macromolecular MRI Contrast Agent. Experimental Biology and Medicine, 2007, 232, 1081-1089.	2.4	68
27	Peptide targeted tripod macrocyclic Gd(III) chelates for cancer molecular MRI. Biomaterials, 2013, 34, 7683-7693.	11.4	67
28	A multifunctional and reversibly polymerizable carrier for efficient siRNA delivery. Biomaterials, 2008, 29, 15-22.	11.4	66
29	Targeted gadofullerene for sensitive magnetic resonance imaging and risk-stratification of breast cancer. Nature Communications, 2017, 8, 692.	12.8	64
30	Extracellular biodegradable macromolecular gadolinium(III) complexes for MRI. Magnetic Resonance in Medicine, 2004, 51, 27-34.	3.0	63
31	Colon-specific 9-aminocamptothecin-HPMA copolymer conjugates containing a 1,6-elimination spacer. Journal of Controlled Release, 2006, 110, 323-331.	9.9	63
32	Gadolinium(III)-based blood-pool contrast agents for magnetic resonance imaging: status and clinical potential. Expert Opinion on Drug Delivery, 2007, 4, 149-164.	5.0	63
33	Synthesis and Evaluation of Nanoglobular Macrocyclic Mn(II) Chelate Conjugates as Non-Gadolinium(III) MRI Contrast Agents. Bioconjugate Chemistry, 2011, 22, 931-937.	3.6	63
34	Molecular imaging of HPMA copolymers: Visualizing drug delivery in cell, mouse and manâ˜†. Advanced Drug Delivery Reviews, 2010, 62, 246-257.	13.7	62
35	Functionalized Semitelechelic Poly[N-(2-hydroxypropyl)methacrylamide] for Protein Modification. Bioconjugate Chemistry, 1998, 9, 793-804.	3.6	57
36	Noninvasive Visualization of in Vivo Drug Delivery of Poly(l-glutamic acid) Using Contrast-Enhanced MRI. Molecular Pharmaceutics, 2006, 3, 507-515.	4.6	57

#	Article	IF	Citations
37	Polymer platforms for drug delivery and biomedical imaging. Journal of Controlled Release, 2007, 122, 269-277.	9.9	57
38	Synthesis and Evaluation of Globular Gd-DOTA-Monoamide Conjugates with Precisely Controlled Nanosizes for Magnetic Resonance Angiography. Biomacromolecules, 2008, 9, 2742-2748.	5.4	57
39	Dendritic nanoglobules with polyhedral oligomeric silsesquioxane core and their biomedical applications. Nanomedicine, 2014, 9, 2387-2401.	3.3	55
40	Targeted Mesoporous Silica Nanoparticles Delivering Arsenic Trioxide with Environment Sensitive Drug Release for Effective Treatment of Triple Negative Breast Cancer. ACS Biomaterials Science and Engineering, 2016, 2, 501-507.	5.2	55
41	Contrast-enhanced MRI with new biodegradable macromolecular Gd(III) complexes in tumor-bearing mice. Magnetic Resonance in Medicine, 2005, 53, 835-842.	3.0	54
42	A targeted nanoglobular contrast agent from host-guest self-assembly for MR cancer molecular imaging. Biomaterials, 2016, 85, 168-179.	11.4	54
43	Contrast-Enhanced MRI-Guided Photodynamic Cancer Therapy with a Pegylated Bifunctional Polymer Conjugate. Pharmaceutical Research, 2008, 25, 2002-2011.	3.5	52
44	Noninvasive Visualization of Pharmacokinetics, Biodistribution and Tumor Targeting of Poly[N-(2-hydroxypropyl)methacrylamide] in Mice Using Contrast Enhanced MRI. Pharmaceutical Research, 2007, 24, 1208-1216.	3.5	50
45	A novel environment-sensitive biodegradable polydisulfide with protonatable pendants for nucleic acid delivery. Journal of Controlled Release, 2007, 120, 250-258.	9.9	48
46	The Polyamine Catabolic Enzyme SAT1 Modulates Tumorigenesis and Radiation Response in GBM. Cancer Research, 2014, 74, 6925-6934.	0.9	48
47	Gadolinium-conjugated TiO2-DNA oligonucleotide nanoconjugates show prolonged intracellular retention period and T1-weighted contrast enhancement in magnetic resonance images. Nanomedicine: Nanotechnology, Biology, and Medicine, 2008, 4, 201-207.	3.3	46
48	Polydisulfide Gd(III) chelates as biodegradable macromolecular magnetic resonance imaging contrast agents. International Journal of Nanomedicine, 2006, 1, 31-40.	6.7	46
49	PEG-g-poly(GdDTPA-co-l-cystine):Â Effect of PEG Chain Length on in Vivo Contrast Enhancement in MRI. Biomacromolecules, 2005, 6, 2305-2311.	5.4	45
50	Integrin Targeted MR Imaging. Theranostics, 2011, 1, 83-101.	10.0	45
51	Pharmacokinetics and Tissue Retention of (Gd-DTPA)-Cystamine Copolymers, a Biodegradable Macromolecular Magnetic Resonance Imaging Contrast Agent. Pharmaceutical Research, 2005, 22, 596-602.	3.5	44
52	Pharmacokinetics, Biodistribution and Contrast Enhanced MR Blood Pool Imaging of Gd-DTPA Cystine Copolymers and Gd-DTPA Cystine Diethyl Ester Copolymers in a Rat Model. Pharmaceutical Research, 2006, 23, 1736-1742.	3.5	44
53	Contrast enhanced MRI-guided photodynamic therapy for site-specific cancer treatment. Magnetic Resonance in Medicine, 2006, 56, 761-767.	3.0	44
54	MR Molecular Imaging of Prostate Cancer with a Peptide-Targeted Contrast Agent in a Mouse Orthotopic Prostate Cancer Model. Pharmaceutical Research, 2012, 29, 953-960.	3.5	44

#	Article	IF	Citations
55	Targeted Contrast Agent Specific to an Oncoprotein in Tumor Microenvironment with the Potential for Detection and Risk Stratification of Prostate Cancer with MRI. Bioconjugate Chemistry, 2017, 28, 1031-1040.	3.6	43
56	Biodegradable cystamine spacer facilitates the clearance of Gd(III) chelates in poly(glutamic acid) Gd-DO3A conjugates for contrast-enhanced MR imaging. Magnetic Resonance Imaging, 2006, 24, 931-940.	1.8	41
57	Multifunctional pH-Sensitive Amino Lipids for siRNA Delivery. Bioconjugate Chemistry, 2016, 27, 19-35.	3.6	41
58	Effect of size and charge on pharmacokinetics and in vivo MRI contrast enhancement of biodegradable polydisulfide Gd(III) complexes. Journal of Controlled Release, 2006, 112, 350-356.	9.9	40
59	Gd³⁺-1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic-2-hydroxypropyl-Î²-cyclodextrin/Pluronic Polyrotaxane as a Long Circulating High Relaxivity MRI Contrast Agent. ACS Applied Materials & Interfaces, 2015, 7, 22272-22276.	8.0	38
60	Targeted Dual pHâ€Sensitive Lipid ECO/siRNA Selfâ€Assembly Nanoparticles Facilitate In Vivo Cytosolic sieIF4E Delivery and Overcome Paclitaxel Resistance in Breast Cancer Therapy. Advanced Healthcare Materials, 2016, 5, 2882-2895.	7.6	38
61	RGD targeted poly(L-glutamic acid)-cystamine-(Gd-DO3A) conjugate for detecting angiogenesis biomarker alpha(v) beta3 integrin with MRT, mapping. International Journal of Nanomedicine, 2007, 2, 191-9.	6.7	38
62	An Effective Targeted Nanoglobular Manganese(II) Chelate Conjugate for Magnetic Resonance Molecular Imaging of Tumor Extracellular Matrix. Molecular Pharmaceutics, 2010, 7, 936-943.	4.6	37
63	Targeted Multifunctional Lipid ECO Plasmid DNA Nanoparticles as Efficient Non-viral Gene Therapy for Leberâ€™s Congenital Amaurosis. Molecular Therapy - Nucleic Acids, 2017, 7, 42-52.	5.1	35
64	Novel Chelated Diorganolithate Ion [CH2SiMe2C(SiMe3)2LiC(SiMe3)2SiMe2CH2]-and Highly Crowded Chelated Organomercury Compound [CH2SiMe2C(SiMe3)2HgC(SiMe3)2SiMe2CH2]. Organometallics, 1996, 15, 1651-1655.	2.3	33
65	Biodistribution and pharmacokinetics of colon-specific HPMA copolymerâ€“9-aminocamptothecin conjugate in mice. Journal of Controlled Release, 2007, 117, 179-185.	9.9	32
66	Characterization of tumor angiogenesis with dynamic contrastâ€enhanced MRI and biodegradable macromolecular contrast agents in mice. Magnetic Resonance in Medicine, 2008, 60, 1347-1352.	3.0	32
67	Non-viral Gene Therapy for Stargardt Disease with ECO/pRHO-ABCA4 Self-Assembled Nanoparticles. Molecular Therapy, 2020, 28, 293-303.	8.2	32
68	Synthesis of Bioadhesive Lectin-HPMA Copolymerâ^'Cyclosporin Conjugates. Bioconjugate Chemistry, 2000, 11, 3-7.	3.6	30
69	Biodegradable iodinated polydisulfides as contrast agents for CT angiography. Biomaterials, 2014, 35, 5822-5829.	11.4	30
70	Selfâ€Assembly of a Multifunctional Lipid With Coreâ€“Shell Dendrimer DNA Nanoparticles Enhanced Efficient Gene Delivery at Low Charge Ratios into RPE Cells. Macromolecular Bioscience, 2015, 15, 1663-1672.	4.1	30
71	Synthesis and Evaluation of pH-Sensitive Multifunctional Lipids for Efficient Delivery of CRISPR/Cas9 in Gene Editing. Bioconjugate Chemistry, 2019, 30, 667-678.	3.6	30
72	Water-soluble HPMA copolymerâ€“wortmannin conjugate retains phosphoinositide 3-kinase inhibitory activity in vitro and in vivo. Journal of Controlled Release, 2001, 74, 275-281.	9.9	29

#	Article	IF	Citations
73	Influence of the structure of drug moieties on the in vitro efficacy of HPMA copolymer-geldanamycin derivative conjugates. Pharmaceutical Research, 2002, 19, 115-123.	3.5	29
74	Synthesis and Evaluation of a Peptide Targeted Small Molecular Gd-DOTA Monoamide Conjugate for MR Molecular Imaging of Prostate Cancer. Bioconjugate Chemistry, 2012, 23, 1548-1556.	3.6	29
75	RNA interference targeting hypoxia-inducible factor 1Î± via a novel multifunctional surfactant attenuates glioma growth in an intracranial mouse model. Journal of Neurosurgery, 2015, 122, 331-341.	1.6	29
76	Improved synthesis and evaluation of 17-substituted aminoalkylgeldanamycin derivatives applicable to drug delivery systems. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 2089-2091.	2.2	26
77	Gd-DTPA l-Cystine Bisamide Copolymers as Novel Biodegradable Macromolecular Contrast Agents for MR Blood Pool Imaging. Pharmaceutical Research, 2006, 23, 1285-1294.	3.5	25
78	Noninvasive Evaluation of Antiangiogenic Effect in a Mouse Tumor Model by DCE-MRI with Gd-DTPA Cystamine Copolymers. Molecular Pharmaceutics, 2010, 7, 41-48.	4.6	25
79	Synthesis and Evaluation of a Nanoglobular Dendrimer 5-Aminosalicylic Acid Conjugate with a Hydrolyzable Schiff Base Spacer for Treating Retinal Degeneration. ACS Nano, 2014, 8, 153-161.	14.6	25
80	Extradomain-B Fibronectin-Targeted Dextran-Based Chemical Exchange Saturation Transfer Magnetic Resonance Imaging Probe for Detecting Pancreatic Cancer. Bioconjugate Chemistry, 2019, 30, 1425-1433.	3.6	25
81	Structural effect on degradability and in vivo contrast enhancement of polydisulfide Gd(III) complexes as biodegradable macromolecular MRI contrast agents. Magnetic Resonance Imaging, 2009, 27, 503-511.	1.8	24
82	New Amphiphilic Carriers Forming pH-Sensitive Nanoparticles for Nucleic Acid Delivery. Langmuir, 2010, 26, 13874-13882.	3.5	24
83	Overexpression of Extradomain-B Fibronectin is Associated with Invasion of Breast Cancer Cells. Cells, 2020, 9, 1826.	4.1	24
84	Synthesis and evaluation of a polydisulfide with Gdâ€“DOTA monoamide side chains as a biodegradable macromolecular contrast agent for MR blood pool imaging. Contrast Media and Molecular Imaging, 2013, 8, 220-228.	0.8	23
85	Molecular MRI of Liver Fibrosis by a Peptide-Targeted Contrast Agent in an Experimental Mouse Model. Investigative Radiology, 2013, 48, 46-54.	6.2	23
86	Conjugation of poorly absorptive drugs with mucoadhesive polymers for the improvement of oral absorption of drugs. Journal of Controlled Release, 2007, 123, 195-202.	9.9	22
87	Polydisulfideâ€based Biodegradable Macromolecular Magnetic Resonance Imaging Contrast Agents. Israel Journal of Chemistry, 2010, 50, 220-232.	2.3	22
88	Magnetic resonance molecular imaging of metastatic breast cancer by targeting extradomainâ€B fibronectin in the tumor microenvironment. Magnetic Resonance in Medicine, 2018, 79, 3135-3143.	3.0	22
89	Optimization of ZD2 Peptide Targeted Gd(HP-DO3A) for Detection and Risk-Stratification of Prostate Cancer with MRI. ACS Medicinal Chemistry Letters, 2018, 9, 730-735.	2.8	22
90	Formulation of Biocompatible Targeted ECO/siRNA Nanoparticles with Long-Term Stability for Clinical Translation of RNAi. Nucleic Acid Therapeutics, 2019, 29, 195-207.	3.6	22

#	Article	IF	Citations
91	Iodo(methoxydimethylsilyl)bis(trimethylsilyl)methane: a reagent for the preparation of novel Chemistry, 1996, 521, 113-120.	1.8	21
92	Efficacy of Targeted ECO/miR-200c Nanoparticles for Modulating Tumor Microenvironment and Treating Triple Negative Breast Cancer as Non-invasively Monitored by MR Molecular Imaging. Pharmaceutical Research, 2021, 38, 1405-1418.	3.5	21
93	Stability and Biodistribution of a Biodegradable Macromolecular MRI Contrast Agent Gd-DTPA Cystamine Copolymers (GDCC) in Rats. Pharmaceutical Research, 2010, 27, 1390-1397.	3.5	20
94	Prolonged prevention of retinal degeneration with retinylamine loaded nanoparticles. Biomaterials, 2015, 44, 103-110.	11.4	20
95	Modification of Gd-DTPA cystine copolymers with PEG-1000 optimizes pharmacokinetics and tissue retention for magnetic resonance angiography. Magnetic Resonance in Medicine, 2007, 58, 110-118.	3.0	19
96	Single cell molecular recognition of migrating and invading tumor cells using a targeted fluorescent probe to receptor PTPmu. International Journal of Cancer, 2013, 132, 1624-1632.	5.1	19
97	Effective MR Molecular Imaging of Triple Negative Breast Cancer With an EDB-Fibronectin-Specific Contrast Agent at Reduced Doses. Frontiers in Oncology, 2019, 9, 1351.	2.8	19
98	Environmentâ€Responsive Lipid/siRNA Nanoparticles for Cancer Therapy. Advanced Healthcare Materials, 2021, 10, e2001294.	7.6	19
99	Synthesis and Assessment of Peptide Gdâ€“DOTA Conjugates Targeting Extradomain B Fibronectin for Magnetic Resonance Molecular Imaging of Prostate Cancer. Molecular Pharmaceutics, 2017, 14, 3906-3915.	4.6	19
100	Tumor Characterization with Dynamic Contrast Enhanced Magnetic Resonance Imaging and Biodegradable Macromolecular Contrast Agents in Mice. Pharmaceutical Research, 2009, 26, 2202-2208.	3.5	18
101	Polydisulfide manganese(II) complexes as nonâ€gadolinium biodegradable macromolecular MRI contrast agents. Journal of Magnetic Resonance Imaging, 2012, 35, 737-744.	3.4	18
102	Theranostics: Fusion of Therapeutics and Diagnostics. Pharmaceutical Research, 2014, 31, 1355-1357.	3.5	18
103	Dynamic Contrast Enhanced MRI Assessing the Antiangiogenic Effect of Silencing HIF-1Î± with Targeted Multifunctional ECO/siRNA Nanoparticles. Molecular Pharmaceutics, 2016, 13, 2497-2506.	4.6	18
104	Modification of Cyclosporin A and Conjugation of Its Derivative to HPMA Copolymers. Bioconjugate Chemistry, 2001, 12, 129-133.	3.6	16
105	Albumin pre-coating enhances intracellular siRNA delivery of multifunctional amphiphile/siRNA nanoparticles. International Journal of Nanomedicine, 2012, 7, 5205.	6.7	16
106	Synthesis of semitelechelic poly[N-(2-hydroxypropyl)methacryl-amide] by radical polymerization in the presence of alkyl mercaptans. Macromolecular Chemistry and Physics, 1999, 200, 2022-2030.	2.2	15
107	N-(2-Hydroxypropyl)methacrylamide Copolymer-9-Aminocamptothecin Conjugate: Colon-Specific Drug Delivery in Rats. Journal of Bioactive and Compatible Polymers, 2002, 17, 305-319.	2.1	15
108	Synthesis and Evaluation of a Targeted Nanoglobular Dual-Modal Imaging Agent for MR Imaging and Image-Guided Surgery of Prostate Cancer. Pharmaceutical Research, 2014, 31, 1469-1476.	3.5	15

#	Article	IF	Citations
109	Molecular Imaging of Tumors Using a Quantitative T1 Mapping Technique via Magnetic Resonance Imaging. Diagnostics, 2015, 5, 318-332.	2.6	15
110	Formulation and efficacy of ECO/pRHO-ABCA4-SV40 nanoparticles for nonviral gene therapy of Stargardt disease in a mouse model. Journal of Controlled Release, 2021, 330, 329-340.	9.9	15
111	Design, synthesis and evaluation of spermine-based pH-sensitive amphiphilic gene delivery systems: Multifunctional non-viral gene carriers. Science China Chemistry, 2011, 54, 359-368.	8.2	14
112	New GABA modulators protect photoreceptor cells from lightâ€induced degeneration in mouse models. FASEB Journal, 2018, 32, 3289-3300.	0.5	14
113	Noninvasive assessment and therapeutic monitoring of drug-resistant colorectal cancer by MR molecular imaging of extradomain-B fibronectin. Theranostics, 2020, 10, 11127-11143.	10.0	14
114	Magnetic Resonance Molecular Imaging of Extradomain B Fibronectin Improves Imaging of Pancreatic Cancer Tumor Xenografts. Frontiers in Oncology, 2020, 10, 586727.	2.8	14
115	Molecular Magnetic Resonance Imaging of Tumors with a PTPÂµ Targeted Contrast Agent. Translational Oncology, 2013, 6, 329-337.	3.7	13
116	Manganese-Enhanced MRI for Preclinical Evaluation of Retinal Degeneration Treatments. , 2015, 56, 4936.		13
117	Anti-angiogenic Effects of Bumetanide Revealed by DCE-MRI with a Biodegradable Macromolecular Contrast Agent in a Colon Cancer Model. Pharmaceutical Research, 2015, 32, 3029-3043.	3.5	13
118	Peptide targeted high-resolution molecular imaging of prostate cancer with MRI. American Journal of Nuclear Medicine and Molecular Imaging, 2014, 4, 525-36.	1.0	13
119	Oxidation of alkene with t-butyl hydroperoxide catalysed by copper(II) complexes of tris(2-benzimidazolylmethyl)amine: Model complexes of blue copper proteins. Journal of Molecular Catalysis, 1991, 70, 391-397.	1.2	12
120	Influence of Molecular Structure on the In Vivo Performance of Flexible Rod Polyrotaxanes. Biomacromolecules, 2016, 17, 2777-2786.	5.4	12
121	Magnetic resonance molecular imaging of extradomain B fibronectin enables detection of pancreatic ductal adenocarcinoma metastasis. Magnetic Resonance Imaging, 2022, 86, 37-45.	1.8	12
122	Synthesis and characterization of (4S)-silatrane-4-carboxylic acids; molecular structure of (3R,4S)-1-vinyl-3-methylsilatrane-4-carboxylic acid. Journal of Organometallic Chemistry, 1993, 446, 107-112.	1.8	11
123	A neutral polydisulfide containing Gd(III) DOTA monoamide as a redoxâ€sensitive biodegradable macromolecular MRI contrast agent. Contrast Media and Molecular Imaging, 2016, 11, 32-40.	0.8	11
124	Chitosan oligosaccharide based Gd-DTPA complex as a potential bimodal magnetic resonance imaging contrast agent. Magnetic Resonance Imaging, 2016, 34, 1-7.	1.8	11
125	Magnetic resonance molecular imaging for non-invasive precision cancer diagnosis. Current Opinion in Biomedical Engineering, 2017, 3, 67-73.	3.4	11
126	Cryo-Imaging and Software Platform for Analysis of Molecular MR Imaging of Micrometastases. International Journal of Biomedical Imaging, 2018, 2018, 1-16.	3.9	11

#	Article	IF	Citations
127	Stable Retinoid Analogue Targeted Dual pH-Sensitive Smart Lipid ECO/pDNA Nanoparticles for Specific Gene Delivery in the Retinal Pigment Epithelium. ACS Applied Bio Materials, 2020, 3, 3078-3086.	4.6	11
128	Stimuliâ€Responsive Nanotheranostics. Advanced Healthcare Materials, 2021, 10, e2100243.	7.6	11
129	Manganese(II) EOB-Pyclen Diacetate for Liver-Specific MRI. ACS Applied Bio Materials, 2022, 5, 451-458.	4.6	11
130	Synthesis and evaluation of nanoglobule-cystamine-(Gd-DO3A), a biodegradable nanosized magnetic resonance contrast agent for dynamic contrast-enhanced magnetic resonance urography. International Journal of Nanomedicine, 2010, 5, 707.	6.7	10
131	Multifunctional PEG Retinylamine Conjugate Provides Prolonged Protection against Retinal Degeneration in Mice. Biomacromolecules, 2014, 15, 4570-4578.	5.4	10
132	Evaluation of Physicochemical Properties, Pharmacokinetics, Biodistribution, Toxicity, and Contrast-Enhanced Cancer MRI of a Cancer-Targeting Contrast Agent, MT218. Investigative Radiology, 2022, 57, 639-654.	6.2	8
133	Regulating Oncogenic LncRNA DANCR with Targeted ECO/siRNA Nanoparticles for Non-Small Cell Lung Cancer Therapy. ACS Omega, 2022, 7, 22743-22753.	3.5	8
134	Ocular Pharmacokinetic Study Using T1 Mapping and Gd-Chelate- Labeled Polymers. Pharmaceutical Research, 2011, 28, 3180-3188.	3.5	7
135	Gadolinium-based contrast agents for magnetic resonance cancer imaging. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2013, 5, 190-190.	6.1	7
136	A novel nonviral gene delivery system for treating Leber's congenital amaurosis. Therapeutic Delivery, 2017, 8, 823-826.	2.2	7
137	New Directions for Drug Delivery in Cancer Therapy. Molecular Pharmaceutics, 2018, 15, 3601-3602.	4.6	7
138	Preparation and Evaluation of ZD2 Peptide ⁶⁴Cu-DOTA Conjugate as a Positron Emission Tomography Probe for Detection and Characterization of Prostate Cancer. ACS Omega, 2019, 4, 1185-1190.	3.5	7
139	Improving Radiation Response in Glioblastoma Using ECO/siRNA Nanoparticles Targeting DNA Damage Repair. Cancers, 2020, 12, 3260.	3.7	7
140	Contrast-Enhanced Magnetic Resonance Angiography with Biodegradable (Gd-DTPA)-Cystamine Copolymers:â€‰ Comparison with MS-325 in a Swine Model. Molecular Pharmaceutics, 2006, 3, 558-565.	4.6	6
141	Intracellular siRNA delivery with novel spermine based surfactants. Science Bulletin, 2012, 57, 3979-3984.	1.7	6
142	Molecular imaging for precision medicine. Advanced Drug Delivery Reviews, 2017, 113, 1-2.	13.7	6
143	Preclinical Assessment of the Effectiveness of Magnetic Resonance Molecular Imaging of Extradomain-B Fibronectin for Detection and Characterization of Oral Cancer. Molecular Imaging and Biology, 2020, 22, 1532-1542.	2.6	6
144	Quantitative analysis of metastatic breast cancer in mice using deep learning on cryo-image data. Scientific Reports, 2021, 11, 17527.	3.3	6

#	Article	IF	Citations
145	Fibronectin in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1245, 85-96.	1.6	6
146	Molecular MRI of atherosclerotic plaque progression in an ApoE(-/-) mouse model with a CLT1 peptide targeted macrocyclic Gd(III) chelate. American Journal of Nuclear Medicine and Molecular Imaging, 2013, 3, 446-55.	1.0	6
147	Application of Biomedical Imaging in Drug Discovery and Development. Pharmaceutical Research, 2007, 24, 1170-1171.	3.5	5
148	Application of a biodegradable macromolecular contrast agent in dynamic contrastâ€enhanced MRI for assessing the efficacy of indocyanine greenâ€enhanced photothermal cancer therapy. Journal of Magnetic Resonance Imaging, 2009, 30, 401-406.	3.4	5
149	Synthesis and characterization of (4S)-1-chloroalkylsilatrane-4-carboxylic acids; cruytal structures of (3R,4S)-1-chloromethyl-3-methylsilatrane-4-carboxylic acid and (3R,4S)-1-(3-chloropropyl)-3-methylsilatrane-4-carboxylic acid. Journal of Organometallic Chemistry, 1995, 489, C38-C43.	1.8	4
150	Role of eIF4E on epithelialâ€mesenchymal transition, invasion, and chemoresistance of prostate cancer cells. Cancer Communications, 2020, 40, 126-131.	9.2	4
151	Peptide Derivatives of Retinylamine Prevent Retinal Degeneration with Minimal Side Effects on Vision in Mice. Bioconjugate Chemistry, 2021, 32, 572-583.	3.6	4
152	Optimization of Synthesis of the Amino Lipid ECO for Effective Delivery of Nucleic Acids. Pharmaceuticals, 2021, 14, 1016.	3.8	4
153	Evaluation of CLT1-(Gd-DTPA) for Cancer MR Molecular Imaging in a Mouse Breast Cancer Model. Bopuxue Zazhi, 2011, 2, 325-330.	1.0	4
154	What Can You See with Imaging in Pharmaceutical Research?. Molecular Pharmaceutics, 2006, 3, 471-471.	4.6	3
155	Cancer Therapy: Targeted Dual pH-Sensitive Lipid ECO/siRNA Self-Assembly Nanoparticles Facilitate In Vivo Cytosolic sieIF4E Delivery and Overcome Paclitaxel Resistance in Breast Cancer Therapy (Adv.) Tj ETQq1 1 0.784314 rgBT /Overlock	8.3	3
156	ECO/siRNA nanoparticles and breast cancer metastasis. Oncoscience, 2015, 2, 823-824.	2.2	0
157	Nanomaterials for Treating Ocular Diseases. Methods in Pharmacology and Toxicology, 2016, , 369-388.	0.2	0
158	Development of Dendrimer-Based Nanomaterials for Diagnostic and Therapeutic Applications. Methods in Pharmacology and Toxicology, 2016, , 47-63.	0.2	0